Your browser doesn't support javascript.
Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months.
Santopaolo, Marianna; Gregorova, Michaela; Hamilton, Fergus; Arnold, David; Long, Anna; Lacey, Aurora; Oliver, Elizabeth; Halliday, Alice; Baum, Holly; Hamilton, Kristy; Milligan, Rachel; Pearce, Olivia; Knezevic, Lea; Morales Aza, Begonia; Milne, Alice; Milodowski, Emily; Jones, Eben; Lazarus, Rajeka; Goenka, Anu; Finn, Adam; Maskell, Nicholas; Davidson, Andrew D; Gillespie, Kathleen; Wooldridge, Linda; Rivino, Laura.
  • Santopaolo M; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Gregorova M; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Hamilton F; Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom.
  • Arnold D; Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom.
  • Long A; Diabetes and Metabolism, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Lacey A; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Oliver E; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Halliday A; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Baum H; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Hamilton K; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Milligan R; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Pearce O; Diabetes and Metabolism, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Knezevic L; Bristol Veterinary School, University of Bristol, Bristol, United Kingdom.
  • Morales Aza B; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Milne A; Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom.
  • Milodowski E; Bristol Veterinary School, University of Bristol, Bristol, United Kingdom.
  • Jones E; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Lazarus R; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
  • Goenka A; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Finn A; Department of Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for Children, Bristol, United Kingdom.
  • Maskell N; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
  • Davidson AD; Department of Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for Children, Bristol, United Kingdom.
  • Gillespie K; School of Population Health Sciences, University of Bristol, Bristol, United Kingdom.
  • Wooldridge L; Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom.
  • Rivino L; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Elife ; 122023 06 13.
Article in English | MEDLINE | ID: covidwho-20242416
ABSTRACT
Coronavirus disease-19 (COVID-19) causes immune perturbations which may persist long term, and patients frequently report ongoing symptoms for months after recovery. We assessed immune activation at 3-12 months post hospital admission in 187 samples from 63 patients with mild, moderate, or severe disease and investigated whether it associates with long COVID. At 3 months, patients with severe disease displayed persistent activation of CD4+ and CD8+ T-cells, based on expression of HLA-DR, CD38, Ki67, and granzyme B, and elevated plasma levels of interleukin-4 (IL-4), IL-7, IL-17, and tumor necrosis factor-alpha (TNF-α) compared to mild and/or moderate patients. Plasma from severe patients at 3 months caused T-cells from healthy donors to upregulate IL-15Rα, suggesting that plasma factors in severe patients may increase T-cell responsiveness to IL-15-driven bystander activation. Patients with severe disease reported a higher number of long COVID symptoms which did not however correlate with cellular immune activation/pro-inflammatory cytokines after adjusting for age, sex, and disease severity. Our data suggests that long COVID and persistent immune activation may correlate independently with severe disease.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Year: 2023 Document Type: Article Affiliation country: ELife.85009

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Year: 2023 Document Type: Article Affiliation country: ELife.85009